# Proteome of Renal Tubuli and Serum Differentiate Pre‐Existing Type 2 Diabetes and Post‐Transplant Diabetes in Kidney Transplant Recipients

## TL;DR

This study compares the proteomes of kidney tubules and serum to distinguish pre-existing type 2 diabetes from post-transplant diabetes in kidney transplant patients.

## Contribution

The first proteomic analysis comparing microdissected tubular cells and serum in post-transplant diabetes and pre-transplant type 2 diabetes.

## Key findings

- PTDM patients show significant dysregulation of mitochondrial proteins and lipid metabolism pathways.
- Serum patterns of cholesterol metabolism are distinct in PTDM compared to T2DM and normoglycemic patients.
- Proteomic differences suggest potential for targeted therapies and early diagnostic markers in PTDM.

## Abstract

Diabetes mellitus (DM) is a major cause of end‐stage kidney disease (ESKD), with kidney transplantation being the preferred treatment. However, post‐transplant diabetes mellitus (PTDM) increases mortality and graft loss. While PTDM and Type 2 diabetes mellitus (T2DM) share risk factors, their mechanisms differ, particularly in diabetic nephropathy (DN). This study aimed to investigate the molecular differences in PTDM by mapping the proteomes of proximal tubuli and serum in normoglycemic (NG), pre‐transplant T2DM, and PTDM patients one year post‐transplantation. Experimental Design Proteomic analysis was performed on microdissected proximal tubular cells and serum samples from kidney transplant recipients categorized as NG, pre‐transplant T2DM, or PTDM at one year post‐transplantation. Mass spectrometry was used to identify differentially expressed proteins. Data analyses were performed using gene ontology databases and pathway analysis.

Proteomic analysis revealed key differences, including significant dysregulation of mitochondrial proteins and lipid metabolism pathways in PTDM patients compared to T2DM and NG groups. Additionally, we observed distinct serum patterns of cholesterol metabolism dysregulation in PTDM, highlighting a complex interplay between fatty acid metabolism, mitochondrial dysfunction and systemic lipid dysregulation that may drive renal injury in PTDM‐related DN.

This pilot study is the first to perform proteomic analysis on both microdissected tubular cells and serum from post‐transplant PTDM, pre‐transplant T2DM and NG transplant recipients. The proteomic differences between PTDM and T2DM could help to develop targeted therapies and early diagnostic markers, ultimately improving transplant outcomes and patient management. Further research is needed to validate these findings and explore their therapeutic potential.